DRUG CLASSIFICA ACTION/INDICATI DOSAGE/ROUTE/FREQ NURSING EVALUATION

NAME TION ON UENCY CONSIDERATION

S
BRAND: Anticonvulsa Inhibiting muscle 1st dose:  Assess  Patient responds
nt contractions by 4 mL / SIVP / 1 ̊ patient’s well to therapy,
blocking calcium condition doesn’t
GENERI receptors 2nd dose: before experience
C:
Magnesi 5 mL / ® buttocks / 1
therapy
and 
convulsions.
Patient does not
um ̊ 45 mins. reassess experience injury
Sulfate Produces a regularly related to drug
peripheral thereafter induced adverse
(predominantly to monitor reactions.
arteriolar) drug  Patient and
vasodilation thus effectivene family state
reducing the blood ss. understanding
pressure  Monitor about drug
respiration, therapy.
watch for
respiratory
May decrease depression
acetylcholine and signs
released by nerve of heart
impulses, but block.
anticonvulsant  Monitor
mechanism is renal
unknown. status.
Assess
INDICATIONS: input-
 Used as an output
anticonvuls ratio.
ant.  Monitor for
 Lowers possible
intracranial drug
pressure. induced
 Prevention adverse
and control reactions:
of seizures CNS:
in toxemia drowsiness,
(preeclamps depressed
ia, reflexes,
 eclampsia). flaccid
 Inhibits paralysis,
uterine hypothermi
contractions a. CV:
in tocolysis hypotensio
(preterm n, flushing,
labor). circulatory
collapse,
depressed
cardiac
function,
heart
block.
Metabolic
:
Hypocalce
mia
Respirato
ry:
paralysis
Skin:
diaphoresis
 Monitor for
signs of
magnesium
toxicity:
disappeara
nce of knee
jerk and
patellar
reflexes
are signs of
early
magnesium
toxicity.
 Assess
prior drug
history;
there are
many drug
interaction
 s

DRUG CLASSIFICATIO ACTION/INDICATIO DOSAGE/ROUTE/FREQU NURSING EVALUATION

NAME N N ENCY CONSIDERATIO
NS
BRAND: Histamine H2 Inhibits histamine at  Use
antagonists H2 receptor site in caution in
Ranitidine presence
the gastric parietal
of renal or
GENERIC: cells, which inhibits
hepatic
gastric acid impairme
Zantac secretion. nt.
 Monitor
INDICATIONS: AST, ALT,
serum
 Used in the creatinine
management ; when
of various use to
gastrointestin prevent
stress-
al (GI)
related GI
disorders. bleeding,
Prophylaxis of occult
GI blood with
hemorrhage GI
bleeding,
from stress
monitor
ulceration renal
and in functionto
patients at correct
risk of dose;
monitor
developing
for side
acid effects
aspiration  Evaluate
during results of
general laboratory
anaesthesia. tests,
therapeuti
c
effectiven
ess and
adverse
reaction.
 Assess
knowledg
e/teach
patient
appropriat
e use,
possible
side
effects /
appropriat
e
interventi
ons and
adverse
symptoms
to report.
Drug name Classification Action/Indication Dosage/Route/Fre Nursing considerations Evaluation
quency

Brand: Corticosteroid Actions: 1st dose:  Obtain patients Patient’s condition

◦ history of improves with
12mgl/IM/ q12
Generic: Enters target cells underlying drug therapy.
Dexamethasone and binds to specific condition before
receptors therapy Patient has no
2nd
dose:  Monitor patients injury as a result
◦ weight and of drug therapy.
12mgl/IM/ q12
glucose level
Initiating many (notify physician Patient and family
complex reactions of weekly gain state
that are responsible >5lbs. or understanding of
for its anti- hyperglycaemia. drug therapy.
inflammatory and  Assess potassium
immune-suppressive depletion or
effects. hypokalemia;
fatigue, nausea,
Indications: vomiting,
depression,
dysrhythmias,
weakness.
 Monitor cardiac
status; blood
pressure, edema,
and chest pain.
 Assess carefully
for infection
because drug can
mask infection;
fever and WBC
even after
withdrawal of
medication.
 Monitor input-
output ratio,
urinary output
and increasing
edema.
 Asssess mental
 status; affect,
mood, behavioral,
changes,
aggression.
 Assess patient’s
and family’s
knowledge on drug
therapy.